Novel compounds for the treatment of HIV type-1 infection

Antiviral Chemistry and Chemotherapy

Volumn 19, Issue 5, 2008, Pages 189-200

  Stellbrink, Hans Jürgen ^a  

^a Infektionsmedizinisches Centrum Hamburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; APRICITABINE; BCH 10618; BMS 707035; CALANOLIDE A; CHEMOKINE RECEPTOR ANTAGONIST; ELVITEGRAVIR; ELVUCITABINE; GRL 02031; GW 695634; IMMUNOMODULATING AGENT; INTEGRASE INHIBITOR; IPILIMUMAB; MARAVIROC; MIV 170; MONOCLONAL ANTIBODY; P 1946; PEGINTERFERON ALPHA2A; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SPI 256; SPI 390; SPI 452; SPI 457; STAMPIDINE; UIC 02031; UK 201844; UK 453061; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC FINGER PROTEIN INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CROSS RESISTANCE; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOTHERAPY; LEUKOPENIA; LOW DRUG DOSE; NONHUMAN; PANCREAS DISEASE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

ANTI-HIV AGENTS; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HUMANS; RECEPTORS, CCR5; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 66349110500     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (142)

1. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
2. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
3. Barreiro P, Jimenez-Nacher I. Garcia B, Garcia-Benayas T, Rivas P, Soriano V. Nucleoside/nucleotide backbones for the treatment of HIV infection. Curr Opin Investig Drugs 2005; 6:812-822.
4. Sabundayo BP, McArthur JH, Langan SJ, Gallant JE, Margolick JB. High frequency of highly active antiretroviral therapy modifications in patients with acute or early human immunodeficiency virus infection. Pharmacotherapy 2006; 26:674-681.
5. Lodwick RK, Smith CJ, Youle M, et al. Stability of antiretroviral regimens in patients with viral suppression. AIDS 2008; 22:1039-1046.
6. Cahn P, Cassetti I, Wood R, et al. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. AIDS 2006; 20:1261-1268.
7. Cahn P, Altclas J, Martins M, Losso M, Cassetti I, Cooper D. Superior activity of apricitabine compared to 3TC over 21 days in treatment experienced HIV-1 infected patients failing therapy with M184V and NRTI resistance. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract WESS203.
8. Colucci P, Cottage J, Robison H, et al. Efficacy and novel pharmacology of elvucitabine in a 7 day placebo controlled monotherapy study. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. 27-30 September 2006, San Francisco, CA, USA. Abstract H-1670d.
9. Dunkle LM, Gathe JC, Pedevillano DE, et al. Elvucitabine: potent antiviral activity demonstrated in multidrug-resistant HIV infection. Antivir Ther 2003; 8:S5
10. Fabrycki J, Zhao Y, Wearne J, et al. In vitro induction of HIV variants with reduced susceptibility to elvucitabine (ACH-126,443, β-1-Fd4C). Antivir Ther 2003; 8:S8
11. Cahn P, Sosa N, Wiznia A, et al. Racivir demonstrates safety and efficacy in patients harboring HIV with the M184V mutation and <3 TAM. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 488.
12. Dalton P. Novel HIV therapy suffers stunning setback. (Updated 12 June 2008. Accessed 12 April 2009.) Available from http://www.projectinform.org/news/2008/1061208.shtml
13. Murphy R, Zala C, Ochoa C, et al. Pharmacokinetics and potent anti-HIV-1 activity of amdoxovir plus zidovudine in a randomized double-blind placebo-controlled study. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 794.
14. Gripshover BM, Ribaudo H, Santana J, et al. Amdoxovir versus placebo with enfuvirtide plus optimized background therapy for HIV-l-infected subjects falling current therapy (AACTG A5118). Antivir Ther 2006; 11:619-623.
15. Margolis DM, Mukherjee AL, Fletcher CV, et al. The use of β-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection. AIDS 2007; 21:2025-2032.
16. Thompson M, Richmond G, Kessler H, et al. Preliminary results of dosing of amdoxovir in treatment-experienced patients. 10th Conference on Retroviruses and Opportunistic Infections. 10-14 February 2003, Boston, MA, USA. Abstract 554.
17. Thompson MA, Kessler HA, Eron JJ, Jr, et al. Short-term safety and pharmacodynamics of amdoxovir in HIV-infected patients. AIDS 2005; 19:1607-1615.
18. Pozniak A, Morales-Ramirez J, Mohapi L, et al. 48-Week primary analysis of trial TMC278-C204: TMC278 demonstrates potent and sustained efficacy in ART-naive patients. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 144LB.
19. Pozniak A, Steyn D, Grinsztejn B, et al. Neuropsychiatric events with TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract WEPEA105.
20. Ruxrungtham K, Bellos N, Morales-Ramirez J, et al. The metabolic profile of TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI). 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, 22-25 July 2007, Sydney, Australia. Abstract TUAB105.
21. van Heeswijk R, Hoetelmans R, Kestens D, et al. The pharmacokinetic interaction between famotidine and TMC278, a next-generation NNRTI, in HIV-negative volunteers. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract TUPDB01.
22. Fatkenheuer G, Staszewski S, Plettenberg A, et al. Short-term monotherapy with UK-453,061, a novel NNRTI, reduces viral load in HIV infected patients. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract WESS202.
23. Wu JJ, Stranix BR, Milot G, et al. PL-100, a next generation protease inhibitor against drug-resistant HIV: in vitro and in vivo metabolism. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. 27-30 September 2006, San Francisco, CA, USA. Abstract H-253.
24. Wu JJ, Daigneault L, Stranix B, et al. Preclinical and clinical evaluation of PPL-100, a next generation HIV protease inhibitor. HIV DART. 10-14 December 2006, Cancun, Mexico. Abstract 83.
25. Markowitz M, Nguyen BY, Gotuzzo E, et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-133.
26. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008; 359:355-365.
27. Steigbigel RT, Cooper DA, Kumar PN, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008; 359:339-354.
28. Zolopa AR, Mullen M, Berger D, et al. The HIV integrase inhibitor GS-9137 has potent antiretroviral activity in treatment-experienced patients. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 143LB.
29. Beatty J, Jacobson J, Lalezari J, et al. Safety and antiviral activity of PA-457, the first-in-class maturation inhibitor, in a 10-day monotherapy study in HIV-1 infected patients. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. 15-19 December 2006, Washington, DC, USA. Abstract LB-27.
30. Martin DE, Blum R, Wilton J, et al. Safety and pharmacokinetics of bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Antimicrob Agents Chemother 2007; 51:3063-3066.
31. Smith P, Forrest A, Beatty J, et al. Pharmacokinetics/ pharmacodynamics of PA-457 in a 10-day multiple dose monotherapy trial in HIV-infected patients. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Abstract 52.
32. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359:1429-1441.
33. Gulick R, Su Z, Flexner C, et al. ACTG 5211: Phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48 week results. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract TUAB102.
34. Gulick RM, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis 2007; 196:304-312.
35. Schurmann D, Fatkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007; 21:1293-1299.
36. Stone ND, Dunaway SB, Flexner C, et al. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects. Antimicrob Agents Chemother 2007; 51:2351-2358.
37. Kuritzkes DR, Jacobson J, Powderly WG, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189:286-291.
38. Norris D, Morales J, Godofsky E, Garcia F, Hardwicke R, Lewis S. TNX-355, in combination with optimized background regimen (OBR), achieves statistically significant viral load reduction and CD4 cell count increase when compared with OBR alone in phase 2 study at week 48. XVI International AIDS Conference. 13-18 August 2006, Toronto, ON, Canada. Abstract ThLB0218.
39. Asmuth D, Chan E, Cai T, et al. A phase II open-label pilot trial of the antiretroviral activity, safety, and tolerability of pegylated interferon-α-2a (40KD) (PegIFN) in HIV-1 infected subjects - ACTG 5192. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract WEPEB079.
40. Dutschman GE, Grill SP, Gullen EA, et al. Novel 4′-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity. Antimicrob Agents Chemother 2004; 48:1640-1646.
41. Bogner JR, Roecken M, Herrmann DB, et al. Phase I/II trial with fozivudine tidoxil (BM 21.1290): a 7 day randomized, placebo-controlled dose-escalating trial. Antivir Ther 1997; 2:257-264.
42. Bogner JR, Boerner D, Muhlhofer A, et al. Single dose, dose-escalating trial with fozivudine tidoxil (BM 21.1290). Antivir Ther 1997; 2:249-256.
43. Girard PM, Pegram PS, Diquet B, et al. Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy. J Acquir Immune Defic Syndr 2000; 23:227-235.
44. Heidelberg Pharma. Clinical effectiveness and tolerability of fosalvudine (HIV) confirmed. (Updated 21 May 2007. Accessed 1 December 2008.) Available from http://www.heidelberg-pharma.com/news/index.html
45. Cahn P, Schürmann D, Reuss F, Wit F, Boehm E, Lange JA. Phase-II study of 14 days monotherapy with the nucleoside-analogue fosalvudine tidoxil in treatment naive HIV-1 infected adults. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract WEPEB114LB.
46. Harris KS, Brabant W, Styrchak S, Gall A, Daifuku R. KP-1212/1461, a nucleoside designed for the treatment of HIV by viral mutagenesis. Antiviral Res 2005; 67:1-9.
47. Skoblov Y, Karpenko I, Shirokova E. Intracellular metabolism and pharmacokinetics of 5′-hydrogenphosphonate of 3′-azido-2′,3′-dideoxythymidine, a prodrug of 3′-azido-2′,3′-dideoxythymidine. Antiviral Res 2004; 63:107-113.
48. Corbett AH, Rublein JC. DAPD (Emory University/Triangle Pharmaceuticals/ Abbott Laboratories). Curr Opin Investig Drugs 2001; 2:348-353.
49. Uckun FM, DuMez D, Qazi S, Tibbles H, Venkatachalam TK. Anti-retroviral activity of GMP-grade stampidine against genotypically and phenotypically nucleoside reverse transcriptase inhibitor resistant recombinant human immunodeficiency virus. An in vitro study. Arzneimittelforschung 2007; 57:112-121.
50. Uckun FM, Venkatachalam TK, Qazi S, Potency of stampidine against multi-nucleoside reverse transcriptase inhibitor resistant human immunodeficiency viruses. Arzneimittelforschung 2006; 56 2A:193-203.
51. Uckun FM. Stampidine as a novel nucleoside reverse transcriptase inhibit with potent anti-HIV activity. Arzneimittelforschung 2006; 56 2A:121-135.
52. Uckun FM, Qazi S, Venkatachalam TK. In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs. Arzneimittelforschung 2005; 55:223-231.
53. Lennerstrand J, Bluemling G, Ruckstuhl M, Bennett M, Chu C, Schinazi R. 1-(β-D-dioxolane) Thymine is effective against HIV-1-containing TAM and M184V. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Abstract 46.
54. Chung KC, Yadav V, Rapp K, Chong Y, Schinazi R. Dioxolane thymine nucleoside is acute against a variety of NRTI-resistant mutants. 12th Conference on Retroviruses and Opportunistic Infections. 22-25 February 2005, Boston, MA, USA. Abstract 554.
55. Liang Y, Narayanasamy J, Schinazi RF, Chu CK. Phosphoramidate and phosphate prodrugs of (-)-β-D-(2R,4R)-dioxolane-thymine: synthesis, anti-HIV activity and stability studies. Bioorg Med Chem 2006; 14:2178-2189.
56. Hernandez-Santiago BI, Chen H, Asif G, et al. Pharmacology and pharmacokinetics of the antiviral agent beta-D-2′,3′-dideoxy-3′-oxa-5-fluorocytidine in cells and rhesus monkeys. Antimicrob Agents Chemother 2005; 49:2589-2597.
57. Yang G, Dutschman GE, Wang CJ, et al. Highly selective action of triphosphate metabolite of 4′-ethynyl d4T: a novel anti-HIV compound against HIV-1 RT. Antiviral Res 2007; 73:185-191.
58. Tanaka H, Haraguchi K, Kumamoto H, Baba M, Cheng YC. 4′-Ethynylstavudine (4′-Ed4T) has potent anti-HIV-1 activity with reduced toxicity and shows a unique activity profile against drug-resistant mutants. Antivir Chem Chemother 2005; 16:217-221.
59. Nitanda T, Wang X, Kumamoto H, et al. Anti-human immunodeficiency virus type 1 activity and resistance profile of 2′,3′-didehydro-3′-deoxy-4′-ethynylthymidine in vitro. Antimicrob Agents Chemother 2005; 49:3355-3360.
60. Kawamoto A, Kodama E, Sarafianos SG, et al. 2′-deoxy-4′-C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int J Biochem Cell Biol 2008; 40:2410-2420.
61. Vere Hodge RA. Highlights of the 20th International Conference on Antiviral Research (ICAR). Future Virol 2007; 2:329-330.
62. Ehteshami M, Deval J, Barry S, Jochmans D, Hertogs K, Götte M. Nucleotide-competing reverse transcriptase inhibitors form a stable dead-end complex with the HIV-1 enzyme. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Abstract 47.
63. Waninger S, Ramos S, Robbins J. Anti-HIV-1 activity of a foscarnet analogue, synergy with zidovudine and analysis of resistance variants selected in vitro. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. 24-27 July 2005, Rio de Janeiro, Brazil. Abstract TuPe6.1B16.
64. Cihlar T, Ray A, Boojamra D, et al. GS9148: a novel nucleotide active against HIV-1 variants with drug resistance mutations in reverse transcriptase. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Abstract 45.
65. Cihlar T, Ray AS, Boojamra CG, et al. Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131. Antimicrob Agents Chemother 2008; 52:655-665.
66. Becker S, Lalezari J, Walworth C, et al. Antiviral activity and safety of GW695634, a novel next generation NNRTI in NNRTI-resistant HIV-1 infected patients. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. 24-27 July 2005, Rio de Janeiro, Brazil. Abstract WePe6.2CO3
67. Eiznhamer DA, Creagh T, Ruckle JL, et al. Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers. HIV Clin Trials 2002; 3:435-450.
68. Creagh T, Ruckle JL, Tolbert DT, et al. Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob Agents Chemother 2001; 45:1379-1386.
69. Coulombe R, Fink D, Landry S, et al. Crystallographic study with BILR 355 BS, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with a broad anti HIV-1 profile. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. 24-27 July 2005, Rio de Janeiro, Brazil. Abstract WePp0105.
70. Huang F, Drda K, Macgregor TR, et al. Pharmacokinetics of BILR 355 after multiple oral doses coadministered with low dose of ritonavir. Antimicrob Agents Chemother 2009; 53:95-103.
71. Jakubik J, Seifer M, Gray L, et al. IDX12899 anti-HIV-1 activity and resistance profile is superior to efavirenz. Antivir Ther 2007; 12:S32.
72. Mayers D, Hard M, Damphousse D, et al. Dose-escalation safety, tolerability, and pharmacokinetics of a novel HIV-1 NNRTI [IDX899] in healthy subjects. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 764.
73. Hamatake R, Xu W, Raney A, et al. An IQ assessment of RDEA806, a potent NNRTI with an excellent activity profile in the presence of human serum proteins. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 731.
74. Yeh L, Ramael S, Comhaire S, et al. Safety and pharmacokinetics of ascending single oral doses of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in healthy volunteers. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. 17-20 September 2007, Chicago, IL, USA. Abstract 1609.
75. Raney A, Hamatake R, Xu W, et al. RDEA427 and RDEA640 are novel NNRTI with potent anti-HIV activity against NNRTI-resistant viruses. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 730.
76. Antiviral briefs. AIDS Patient Care STDS 2006; 20:887-889.
77. Kodama E, Orita M, Masuda N, et al. Binding modes of two novel non-nucleoside reverse transcriptase inhibitors, YM-215389 and YM-228855, to HIV type-1 reverse transcriptase. Antivir Chem Chemother 2008; 19:133-141.
78. Buckheit RW, Jr, Watson K, Fliakas-Boltz V, et al. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob Agents Chemother 2001; 45:393-400.
79. Kaludov N, Watson K, Buckheit R, Jr. Investigational new drug-directed development of IQP-0410, a safe and highly potent dual-acting nonnucleoside pyrimidinedione for the therapy of HIV-1 infection. 16th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2009, Montreal, QC, Canada. Abstract 558.
80. Klumpp K, Dunn J, Heilek G, et al. R1206, a representative of a new class of potent diphenyl ether non-nucleoside reverse transcriptase inhibitors broadly active against NNRTI-resistant HIV-1 variants and achieving high systemic exposures and benign safety profiles in animal species. Antivir Ther 2007; 12:S30.
81. Sweeney ZK, Harris SF, Arora N, et al. Design of annulated pyrazoles as inhibitors of HIV-1 reverse transcriptase. J Med Chem 2008; 51:7449-7458.
82. Sweeney ZK, Kennedy-Smith JJ, Wu J, et al. Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties. ChemMedChem 2009; 4:88-99.
83. Cirne-Santos CC, Teixeira VL, Barreto-de-Souza V, Castello-Branco LR, Frugulhetti ICPP, Bou-Habib DC. The diterpene TRIOL inhibits HIV-1 infection mediated by primary isolates with distinct chemokine receptor usage. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. 24-27 July 2005, Rio de Janeiro, Brazil. Abstract TuPe6.1B04.
84. Dandache S, Sevigny G, Yelle J, et al. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2007; 51:4036-4043.
85. Hammond J, Jackson L, Graham J, et al. Antiviral activity and resistance profile of AG-001859, a novel HIV-1 protease inhibitor with potent activity against protease inhibitor-resistant strains of HIV. Antivir Ther 2004; 9:S17.
86. Mimoto T, Nojima S, Terashima K, Takaku H, Shintani M, Hayashi H. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure. Bioorg Med Chem 2008; 16:1299-1308.
87. Sevigny G, Stranix B, Tian B, et al. Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor. Antiviral Res 2006; 70:17-20.
88. Gulnik S, Afonina E, Eissenstat M, Parkin N, Japour A, Erickson J. SPI-256, a highly potent HIV protease inhibitor with broad activity against MDR strains. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Abstract 501.
89. Afonina E, Gulnik S, Eissenstat M, et al. Highly potent protease inhibitors with novel escape pathways. Antivir Ther 2007; 12:S21.
90. Koh Y, Das D, Leschenko S, et al. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro. Antimicrob Agents Chemother 2009; 53:997-1006.
91. Koh Y, Nakata H, Ogata-Aoki H, Leschenko S, Ghosh A, Mitsuya H. UIC-02031: a novel nonpeptidic protease inhibitor containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant HIV-I in vitro. 12th Conference on Retroviruses and Opportunistic Infections. 22-25 February 2005, Boston, MA, USA. Abstract 562.
92. Bristol-Myers Squibb. Trial details for trial AI441-008. (Updated 24 August 2007. Accessed 1 December 2008.) Available from http://ctr.bms.com/OneBmsCtd/InitTrialDetailAction.do?pnum=AI441-008
93. Reddy YS, Min SS, Borland J, et al. Safety and pharmacokinetics of GSK364735, a human immunodeficiency virus type 1 integrase inhibitor, following single and repeated administration in healthy adult subjects. Antimicrob Agents Chemother 2007; 51:4284-4289.
94. McDougall B, King PJ, Wu BW, Hostomsky Z, Reinecke MG, Robinson WE, Jr. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 1998; 42:140-146.
95. Li F, Goila-Gaur R, Salzwedel K, et al. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc Natl Acad Sci U S A 2003; 100:13555-13560.
96. McCallister S, Doto J, Allaway G, Martin DE. Multiple dosing of the novel HIV-1 maturation inhibitor bevirimat (BVM): aggregate adverse event (AE) and laboratory data from four short-term studies. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract WEPEA110.
97. Kilgore N, Reddick M, Zuiderhof M, et al. Characterization of PA1050040, a second generation HIV-1 maturation inhibitor. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract MOPDX05.
98. + T cells. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract WEPEA089.
99. Blair W, Cao J, Jackson L, et al. Execution of a high throughput HIV-1 replication screen and the identification of a novel small molecule inhibitor that targets HIV-1 envelope maturation. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Abstract 50 LB.
100. Rice WG, Turpin JA, Huang M, et al. Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nat Med 1997; 3:341-345.
101. Goebel FD, Hemmer R, Schmit JC, et al. Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy. AIDS 2001; 15:33-45.
102. Berkhout B, Gorelick R, Summers MF, Mély Y, Darlix JL. 6th international symposium on retroviral nucleocapsid. Retrovirology 2008; 25:21.
103. Zhang XQ, Sorensen M, Fung M, Schooley RT. Synergistic in vitro antiretroviral activity of a humanized monoclonal anti-CD4 antibody (TNX-355) and enfuvirtide (T-20). Antimicrob Agents Chemother 2006; 50:2231-2233.
104. Jacobson JM, Kuritzkes DR, Godofsky E, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 2009; 53:450-457.
105. Pett S, Emery S, MacRae K, et al. Safety and activity of SCH532706, a small molecule chemokine receptor 5 antagonist in HIV-l-infected individuals. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 38.
106. Cohen C, DeJesus E, Mills A, et al. Potent antiretroviral activity of the once-daily CCR5 antagonist INCB009471 over 14 days of monotherapy. 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 22-25 July 2007, Sydney, Australia. Abstract TUAB106.
107. Jacobson JM, Saag MS, Thompson MA, et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 2008; 198:1345-1352.
108. Giguel F, Beebe L, Migone TS, Kuritzkes D. The anti-CCR5 mAb004 inhibits HIV-1 replication synergistically in combination with other antiretroviral agents but does not select for resistance during in vitro passage. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Abstract 505.
109. Lalezari J, Yadavalli GK, Para M, et al. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-l-infected patients. J Infect Dis 2008; 197:721-727.
110. Dorr P, Westby M, McFadyen L, et al. PF-232798, a second generation oral CCR5 antagonist. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 737.
111. Jekle A, Kondru R, Ki C, et al. CCR5 binding properties of a CCR5 small-molecule inhibitor with high antiviral potency against a maraviroc-resistant HIV-1 strain. Antivir Ther 2007; 12:S13.
112. Schols D, Vermeire K, Fransen S, et al. Multi-drug resistant HIV-1 is sensitive to inhibition by chemokine receptor antagonists. 12th Conference on Retroviruses and Opportunistic Infections. 22-25 February 2005, Boston, MA, USA. Abstract 545.
113. Baba M, Takashima K, Miyake H, et al. TAK-652 inhibits CCR5-mediated human immunodeficiency virus type 1 infection in vitro and has favorable pharmacokinetics in humans. Antimicrob Agents Chemother 2005; 49:4584-4591.
114. Ferain O, Schols D, Bernard J, et al. ESN-196, a novel, small-molecule CCR5 agonist inhibits R5 HIV infection. 15th Conference on Retroviruses and Opportunistic Infections. 3-6 February 2008, Boston, MA, USA. Abstract 738.
115. Moyle G, DeJesus E, Boffito M, et al. CXCR4 antagonism: proof of activity with AMD11070. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 511.
116. Saag M, Rosenkranz S, Becker S, et al. Proof of concept of antiretroviral activity of AMD 11070 (an orally administered CXCR4 entry inhibitor): results of the first dosing cohort A studied in ACTG Protocol A5210. 14th Conference on Retroviruses and Opportunistic Infections. 25-28 February 2007, Los Angeles, CA, USA. Abstract 512.
117. Murakami T, Yoshida A, Tanaka R, et al. KRH-2731: an orally bioavailable CXCR4 antagonist Is a potent inhibitor of HIV-1 infection. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 541.
118. Castagna A, Biswas P, Beretta A, Lazzarin A. The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs 2005; 65:879-904.
119. Tanaka Y, Okuma K, Tanaka R, et al. Development of novel orally bioavailable CXCR4 antagonists, KRH-3955 and KRH-3140: binding specificity, pharmacokinetics and anti-HIV-1 activity in vivo and in vitro. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Abstract 49LB.
120. Moncunill G, Armand-Ugon M, Clotet-Codina I, et al. Anti-HIV activity and resistance profile of the CXC chemokine receptor 4 antagonist POL3026. Mol Pharmacol 2008; 73:1264-1273.
121. Zhang LJ. A bis-azo-dye (FP-21399) inhibits HIV-1 replication in the post-absorption stage. 4th Conference on Retroviruses and Opportunistic Infections. 22-26 July 1997 Washington DC, USA. Abstract 217.
122. Dezube BJ, Dahl TA, Wong TK, et al. A fusion inhibitor (FP-21399) for the treatment of human immunodeficiency virus infection: a Phase I study. J Infect Dis 2000; 182:607-610.
123. Poli G, Vicenzi E. FP-21399 (Lexigen Pharmaceuticals). IDrugs 2001; 4:1293-1295.
124. Dai SJ, Dou GF, Qiang XH, et al. Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro. Acta Pharmacol Sin 2005; 26:1274-1280.
125. Dai SJ, Dou GF, Qiang XH, et al. Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro. Acta Pharmacol Sin 2005; 26:1274-1280.
126. He Y, Xiao Y, Song H, et al. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 2008; 283:11126-11134.
127. Dove A. New class of HIV drugs shows promise. Nat Med 2001; 7:1265.
128. de Mareuil J, Mabrouk K, Doria E, et al. Liposomal encapsulation enhances antiviral efficacy of SPC3 against human immunodeficiency virus type-1 infection in human lymphocytes. Antiviral Res 2002; 54:175-188.
129. Samaritan Pharmaceuticals. Samaritan partnered its phase II SP-01A HIV drug to pharmaplaz, Ireland. (Updated 28 August 2007. Accessed 1 December 2008.) Available from http://www.samaritanpharma.com/ aids_hiv_program_sp-01a.asp
130. Wang X, Douglas SD, Lai J-P, Tuluc F, Tebas P, Ho W. Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. J Neuroimmune Pharmacol 2007; 2:42-48.
131. Munch J, Standker L, Adermann K, et al. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 2007; 129:263-275.
132. Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin Biol Ther 2007; 7:1245-1256.
133. Farrell A. Defeating T-cell fatigue in HIV. Nat Med 2006; 12:1124-1125.
134. Hauber I, Bevec D, Heukeshoven J, et al. Identification of cellular deoxyhypusine synthase as a novel target for antiretroviral therapy. J Clin Invest 2005; 115:76-85.
135. Haffar O, Dubrovsky L, Lowe R, et al. Oxadiazols: a new class of rationally designed anti-human immunodeficiency virus compounds targeting the nuclear localization signal of the viral matrix protein. J Virol 2005; 79:13028-13036.
136. Dezube BJ, Proper J, Zhang J, et al. A passive immunotherapy, (PE)HRG214, in patients infected with human immunodeficiency virus: a Phase I study. J Infect Dis 2003; 187:500-503.
137. Pett SL, Williams LA, Day RO, et al. A Phase I study of the pharmacokinetics and safety of passive immunotherapy with caprine anti-HIV antibodies, (PE)HRG214, in HIV-1-infected individuals. HIV Clin Trials 2004; 5:91-98.
138. PEHRG214 (HRG); anti-HIV activity and mapping of novel antibody specificities. 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment. 24-27 July 2005, Rio de Janeiro, Brazil. Abstract WePe6.2C02.
139. Trkola A, Kuster H, Rusert P, et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005; 11:615-622.
140. Manrique A, Rusert P, Joos B, et al. In vivo and in vitro
141. Matsushita S, Takahama S, Shibata J, et al. Ex vivo neutralization of HIV-1 quasi-species by a broadly reactive humanized monoclonal antibody KD-247. Hum Antibodies 2005; 14:81-88.
142. Yoshimura K, Shibata J, Kimura T, et al. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors. AIDS 2006; 20:2065-2073.